Circulating senescent myeloid cells drive blood brain barrier breakdown and neurodegeneration

C. Matthias Wilk[1-3], Flurin Cathomas[4-5#], Orsolya Török[6#], Jessica Le Berichel[1-3#], Matthew D. Park[1-3#], George R. Heaton[7], Pauline Hamon[1-3], Leanna Troncoso[1-3], Brooks P. Scull[8], Diana Dangoor[9-13], Aymeric Silvin[14-15], Ryan Fleischmann[8], Meriem Belabed[1-3], Howard Lin[8], Elias Merad Taouli[1-3], Steffen Boettcher[16], Markus G. Manz[16], Julia K. Kofler[17], Zhenyu Yue[7], Sergio A. Lira[1], Florent Ginhoux[14-15], John F. Crary[9-13], Kenneth L. McClain[8], Jennifer L. Picarsic[18], Scott J. Russo[4-5], Carl E. Allen[8#*] and Miriam Merad[1-3#*]

1 Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 Department of Oncology Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
4 Nash Family Department of Neuroscience, Brain & Body Research Center, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5 Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
6 Department of Neurology, University of Pécs, Medical School, Pécs, Hungary
7 Department of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
8 Texas Children's Cancer Center, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
9 Department of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
10 Department of Artificial Intelligence, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
11 Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
12 Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
13 Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
14 Gustave Roussy Cancer Campus, Villejuif, France
15 Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée—Ligue Nationale contre le Cancer, Villejuif, France
16 Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland
17 Division of Neuropathology, Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
18 Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
[#] indicates equal contribution
[*] indicates corresponding authors

Correspondence:
miriam.merad@mssm.edu
ceallen@texaschildrens.org

Word / item counts:
Word count: 3933/6000
Summary word count: 150/150
Display items count: 4/7
References: 38/50
Supplementary Figures & Tables: 7/8

1 **Summary (150/150)**

2

3 Neurodegenerative diseases (ND) are characterized by progressive loss of neuronal function.

4 Mechanisms of ND pathogenesis are incompletely understood, hampering the development of

5 effective therapies. Langerhans cell histiocytosis (LCH) is an inflammatory neoplastic disorder

6 caused by hematopoietic progenitors expressing MAPK activating mutations that differentiate into

7 senescent myeloid cells that drive lesion formation. Some patients with LCH subsequently develop

8 progressive and incurable neurodegeneration (LCH-ND). Here, we show that LCH-ND is caused by

9 myeloid cells that are clonal with peripheral LCH cells. We discovered that circulating $BRAF$V600E$^+$

10 myeloid cells cause the breakdown of the blood-brain barrier (BBB), enhancing migration into the

11 brain parenchyma where they differentiate into senescent, inflammatory CD11a$^+$ macrophages that

12 accumulate in the brainstem and cerebellum. Blocking MAPK activity and senescence programs

13 reduced parenchymal infiltration, neuroinflammation, neuronal damage and improved neurological

14 outcome in preclinical LCH-ND. MAPK activation and senescence programs in circulating myeloid

15 cells represent novel and targetable mechanisms of ND.

16

1   **Keywords (5/10):**
2   Histiocytic Disorders, Langerhans Cell Histiocytosis, Neurodegeneration, Blood Brain Barrier,
3   Neuroinflammation
4
5

1   **Introduction**

2

3   Neurodegenerative diseases (ND) are characterized by progressive loss of neuronal function.

4   Mechanisms of ND pathogenesis are incompletely understood, hampering the development of

5   effective therapies. A progressive, incurable neuroinflammatory condition (LCH-ND) arises in

6   approximately 10% of patients with Langerhans cell histiocytosis (LCH)[1,2]. LCH is an inflammatory

7   neoplastic disorder caused by hematopoietic progenitors expressing MAPK activating mutations that

8   differentiate into senescent mononuclear phagocytes (MNP) that drive lesion formation[3,4]. LCH

9   therefore represents an informative disease model to investigate mechanisms by which

10   hematopoietic myeloid cells can induce neuroinflammation and neurodegeneration.

11

12   LCH-ND is a devastating complication of LCH patients that can arise years after the initial systemic

13   disease is cured. Clinically, LCH-ND is characterized by progressive inflammatory lesions in the

14   cerebellum, basal ganglia and brainstem with associated progressive neurologic clinical findings

15   including ataxia, dysarthria and dysmetria[5]. LCH-ND was initially considered a para-neoplastic or

16   auto-immune condition, due to the lack of CD207[+] cells typically observed in systemic LCH lesions

17   and the presence of T cell infiltrates in the rare cases of reported biopsies[6,7]. Optimal strategies for

18   surveillance and treatment of LCH are poor, and the etiology of LCH-ND remains uncertain.

19   Historically, therapeutic approaches for LCH-ND included observation, immune suppression and

20   chemotherapy[1,8,9].

21

22   We have previously demonstrated that multisystem LCH is caused by MAPK activating mutations,

23   (most commonly *BRAF*V600E) that occur in early hematopoietic progenitors[10,11]. We validated

24   *BRAF*V600E as a driver mutation that recapitulated the LCH phenotype, when expression was

25   enforced in myeloid progenitors[10]. We further demonstrated that the *BRAF*V600E mutation induces

26   an oncogene-driven senescence program in early hematopoietic precursors that reduces their

27   proliferation potential. In these cells, survival is supported by expression of anti-apoptotic molecules

28   such as Bcl-xL and senescence-associated secretory proteins (SASP) that skew the differentiation of

29   *BRAF*V600E[+] hematopoietic progenitors into senescent MNP that seed peripheral tissues[3].

30   Senescent MNP that accumulate in tissues drive the formation of inflammatory and granulomatous

31   LCH lesions, leading to tissue damage. Notably, therapies that block SASP and dis-inhibit resistance

32   to cell death decrease disease burden and prolong survival in mouse models[3].

33

1   The relationship between systemic LCH and LCH-ND is not well defined. There are associations

2   between the risk of developing LCH-ND and disseminated LCH, progressive or relapsed systemic

3   disease, *BRAF*V600E mutation, and lesions in the skull base, the pituitary and brain parenchyma[5].

4   Importantly, we recently identified circulating *BRAF*V600E[+] peripheral blood mononuclear cells

5   (PBMC) in the blood of patients with LCH-ND, even in the absence of active systemic lesions. We

6   also detected *BRAF*V600E[+] myeloid cells in brain biopsies of patients with LCH-ND[3,12] and

7   demonstrated that, similar to peripheral LCH cells, pathogenic MNP that accumulate in the brain of

8   human LCH-ND exhibit features of senescence[3]. Based on these observations and the clinical

9   patterns of LCH-ND, we hypothesized that LCH-ND arises from hematopoietic precursors that are

10   clonal with peripheral LCH lesions and that senescence programs in infiltrating myeloid cells may

11   also contribute to brain injury in patients with LCH-ND.

12

13   Taking advantage of the LCH model of persistent MAPK activation in hematopoietic cells, we sought

14   to define mechanisms by which MAPK activation in MNP could drive neuroinflammation and

15   neurodegeneration. Resident and recruited MNP populations in the central nervous system (CNS)

16   are increasingly recognized to play central roles in a wide range of neurodegenerative conditions[13]

17   by orchestrating immune cell activation. This study highlights a novel mechanism for monocyte-

18   derived CD11a[+] macrophages to induce CNS neurodegenerative diseases that can be reversed with

19   MAPK inhibition and senolytic therapy.

20

Results

Genetic fate-mapping reveals that circulating *BRAF*V600E$^+$ myeloid cells accumulate in the brains of mice with LCH-like disease

To study the potential cellular determinants of LCH-ND, we designed transgenic mice that express *BRAF*V600E, the most common somatic mutation in LCH, at different stages of hematopoietic differentiation, recapitulating key features of LCH[3,10]. Specifically, we found that multi-system LCH developed in mice, in which we enforced the *BRAF*V600E mutation under the promoter of the *Scl* gene that is expressed in long-term and short-term hematopoietic stem cells (HSC) in the bone marrow and showed that *BRAF*V600E$^+$ MNP were the main drivers of tissue injury in the periphery[3].

To explore whether LCH-ND was also driven by circulating *BRAF*V600E$^+$ cells, we used the above model of LCH models in which a conditional *BRAF*V600E mutation was enforced under the promoter of the *Scl* gene (**Fig. 1a**). As previously described, we genetically engineered somatic mosaicism for a *BRAF*V600E allele linked to a yellow fluorescent protein (YFP) in HSC using tamoxifen (Tam)-inducible targeting in *Scl*^{creERT} mice, which we named *BRAF*V600E^{Scl} and used *BRAF* wild-type (*BRAF*wt^{Scl}) as control littermates. Thus, YFP-expressing cells carried the *BRAF*V600E mutation in *BRAF*V600E^{Scl} mice, whereas YFP-expressing cells in *BRAF*wt^{Scl} animals did not carry the mutation but underwent Rosa26-locus driven Cre recombination. Strikingly, in addition to systemic LCH lesions, we also detected YFP-reporter-tagged, *BRAF*V600E-mutated cells in the brains of *BRAF*V600E^{Scl} animals between week 8 and 12 after tamoxifen-induced cre-recombination (**Fig. 1b**). We further characterized these cells as CD11a$^+$ macrophages, a monocyte-derived population recently described in the CNS vasculature as having the potential to infiltrate brain parenchyma[14]. The population of CD11a$^+$ macrophages was the only myeloid cell population expressing the *BRAF*V600E mutation in the brains of *BRAF*V600E^{Scl} mice. This CD11a$^+$ macrophage population was also enriched up to 50-fold compared to control animals. *BRAF*V600E$^+$ cells were notably not detected in either microglia or perivascular macrophages (PVM) (**Fig. 1b**). The percentage of YFP-tagged cells in the brains of mice correlated with the percentage of reporter-tagged cells in the peripheral blood and was significantly higher in *BRAF*V600E^{Scl} animals compared to *BRAF*wt^{Scl} animals (**Fig. 1c**).

To confirm whether *BRAF*V600E$^+$ macrophages that accumulated in the brain of *BRAF*V600E^{Scl} animals arose from circulating precursors and not locally, we developed another model of MAPK activating mutations expressed exclusively in bone marrow HSC by enforcing *BRAF*V600E mutation under the *Map17* gene promoter known to be expressed in long-term bone marrow HSC, which we

1 refer to as *BRAF*V600E^{Map17} mice (**Fig. 1A**)[15]. Similar to the *BRAF*V600E^{Scl} model, *BRAF*V600E^{Map17}

2 mice developed systemic LCH lesions (**Fig. S1a-b**), again emphasizing that multisystem LCH is a

3 myeloid inflammatory neoplasia driven by MAPK activating mutation expressed in early HSC[4].

4 Importantly and similar to *BRAF*V600E^{Scl} mice, we detected a large population of *BRAF*V600E$^+$

5 CD11a$^+$ macrophages in the brain parenchyma of *BRAF*V600E^{Map17} mice between week 12 and 16

6 after tamoxifen-induced Cre recombination (**Fig. S1c-d**), suggesting that circulating *BRAF*V600E$^+$

7 myeloid cells indeed give rise to *BRAF*V600E$^+$ CD11a$^+$ macrophages.

8

9 To further ensure that *BRAF*V600E$^+$ CD11a$^+$ macrophages which accumulated in the brain of these

10 mice derived from circulating mutated cells and did not arise locally, we generated bone marrow

11 chimeric animals (CD45.2 *BRAF*V600E^{Scl}:CD45.1 wild-type) animals in which bone marrow cells

12 isolated from *BRAF*V600E^{Scl} or lineage tracing control mice (*BRAF*wt^{Scl}) were injected into CD45.1$^+$

13 congenic host mice (**Fig. 1d**). In order to prevent damage to the blood brain barrier (BBB) induced by

14 pre-transplant conditioning that could artifactually promote translocation of circulating cells into the

15 brain parenchyma, host mice were irradiated with a lead head-shield, as previously described[16]. We

16 found that similar to transgenic mice, chimeric mice also developed systemic LCH lesions (**Fig. S1e-**

17 **f**) as well as brain lesions with accumulation of *BRAF*V600E CD11a$^+$ macrophages (**Fig. 1e, Fig.**

18 **S1e-f**). Of note, chimeric mice transplanted with BM from *BRAF*wt^{Scl} and *BRAF*V600E^{Scl} donor mice

19 did not differ in terms of donor chimerism (**Fig. S1g**). CD11a$^+$ macrophages originated from the

20 donor bone marrow (CD45.2$^+$) and expressed high levels of the cell type-defining integrin alpha L

21 (CD11a) but lacked the expression of markers of PVM (e.g., CD169, LYVE-1, CD206) and showed

22 modest induction of tissue resident microglia markers (e.g., P2RY12) (**Fig. 1f**), confirming that these

23 cells do not present cues of local resident origin.

24

25 We next sought to determine whether CD11a$^+$ macrophages remained restricted to the vasculature

26 or had the potential to invade the brain parenchyma. We intravenously injected *BRAF*V600E^{Scl} mice

27 with an anti-CD45 antibody conjugated to a fluorescent dye to tag intravascular cells prior to brain

28 isolation and analysis (**Fig. 1g**). Nearly 50% of brain associated CD11a$^+$ macrophages were

29 unstained, suggesting that a substantial fraction of the CD11a$^+$ macrophages while derived from the

30 blood circulation, had extravasated into the brain parenchyma of *BRAF*V600E^{Scl} mice (**Fig. 1h**).

31

32 **LCH mice with brain-infiltrating *BRAF*V600E-mutated cells share phenotypic and**

33 **transcriptional characteristics with human LCH-ND**

1   In humans, imaging studies and clinical features typically localize LCH lesions and CNS injury to the
2   brainstem (pons, medulla oblongata) and cerebellum as well as to areas with limited BBB (pituitary,
3   vermis, choroid plexus)[5]. We recently reported enrichment of *BRAF*V600E[+] cells in brainstem and
4   cerebellum with minimal infiltration in the temporal and frontal lobes of a whole brain autopsy from a
5   young man who died from progressive LCH-ND[17] (**Fig. 2a-b**). Remarkably, the pattern of
6   neurodegeneration in human LCH-ND matched the main sites of parenchymal infiltration in the
7   *BRAF*V600E*[Scl]* chimera (**Fig. 2c-d**). Of note, the infiltration pattern in our *BRAF*V600E*[Scl]* chimera
8   was diffuse with a lack of granulomatous lesions (**Fig. 2e,** right**)**. By comparison, reporter-tagged
9   cells were virtually absent in brain tissue from the control chimera (**Fig. 2e**, left).
10
11   To further establish the pathogenic role of blood-derived *BRAF*V600E[+] CD11a[+] macrophages, we
12   profiled purified CD11a[+] macrophages, peripheral blood monocytes and microglia from
13   *BRAF*V600E*[Scl]* and *BRAF*wt*[Scl]* mice using bulk RNA sequencing (bulk RNAseq). In comparing the
14   mRNA transcriptome profiles of subsets of each myeloid cell subset from *BRAF*wt*[Scl]* and
15   *BRAF*V600E*[Scl]* mice (**Fig. 2f-h**), we generated a deviance score to represent the divergence of gene
16   expression driven by the *BRAF*V600E mutation, wherein a score of 0 would indicate complete
17   concordance between genotypes (**Fig. 2i**). We found that the transcriptomic differences observed in
18   mutant versus wild-type CD11a[+] macrophages were the most dramatic, compared to that computed
19   for *BRAF*V600E[+] and wild-type monocytes and microglia (**Fig. 2i**), suggesting that the induction of
20   the MAPK pathway activation by *BRAF*V600E significantly impacts the molecular phenotype of the
21   CD11a[+] macrophages, in line with the anticipated effect of Cre recombination in *BRAF*V600E*[Scl]*
22   mice. Of note, while monocytes from *BRAF*V600E*[Scl]* mice harbor the *BRAF*V600E mutation,
23   microglia from *BRAF*V600E*[Scl]* mice does not.
24   We had previously shown that an oncogene-induced senescence program is the driver of
25   inflammation in CD207[+] cells that infiltrate systemic LCH lesions[3]. Thus, we measured the
26   expression of canonical senescence genes in wild-type and *BRAF*V600E CD11a[+] macrophages and
27   confirmed upregulation of senescence-related genes in *BRAF*V600E*[Scl]* CD11a[+] macrophages,
28   compared to wild-type cells. Among these upregulated genes, we identified cell cycle control genes
29   encoding the anti-apoptotic Bcl-2 family member Bcl-xL (*Bcl2l1*), uPAR (*Plaur*), and matrix
30   metalloproteinases, which are all classically upregulated during oncogene-induced senescence (**Fig.
31   2j**). In addition, *BRAF*V600E[+] CD11a[+] macrophages overexpressed several integrin sub-units in
32   addition to αL (CD11a, *Itgal*) including subunits α4 (*Itga4*), α5 (*Itga5*), α6 (*Itga6*) and β1 (*Itgb1*),
33   suggesting a potential role for this integrin program in mediating infiltration of brain tissue by
34   *BRAF*V600E[+] CD11a[+] macrophages (**Fig. 2k)**. CXCR4 was expressed on CD11a[+] macrophages, in

1 line with our observation that these are bone marrow-derived cells (**Fig. 2k**). We also compared this

2 transcriptional dataset to a case of LCH-ND, for which an RNAseq data set is publicly available[18].

3 Consistent with our observations in mice, we found that mRNA expression of the lineage genes

4 depicted in **Fig 2k** was more enriched in human LCH-ND, than in bulk profiling of healthy human

5 brain myeloid cells (**Fig. 2l**). In a more comprehensive analysis, we generated a shared mRNA

6 library between our murine bulk RNAseq dataset from CD11a$^+$ macrophages from *BRAF*V600E^{Scl}

7 mice with the published dataset of healthy and LCH-afflicted brain tissue – akin to published

8 strategies applied for single-cell transcriptomic datasets[19,20]. We compared the expression patterns

9 of genes that are enriched in murine *BRAF*V600E$^+$ CD11a$^+$ macrophages, compared to their wild-

10 type counterparts, with those differentially expressed between human LCH-ND and healthy human

11 brain tissue. From this homology analysis, we found that nearly 60% of genes enriched in

12 *BRAF*V600E$^+$ CD11a$^+$ macrophages are also more highly expressed in human LCH-ND, indicating

13 significant concordance between the transcriptional activity between human LCH-ND and brain

14 infiltration by CD11a$^+$ macrophages in our mouse model (**Fig. 2m**), supporting the likely contribution

15 of the gene program of CD11a$^+$ macrophages in human LCH-ND, analogous to its role in our murine

16 model of LCH-ND.

17

18 **BRAFV600E^{Scl} chimera have a compromised BBB and exhibit behavioral and neurologic**

19 **abnormalities**

20 Systemic inflammation has been shown to alter the BBB and promote the extravasation of circulating

21 myeloid cells into the brain[13]. Because senescence and systemic inflammation are hallmark features

22 of LCH, we sought to examine whether BBB is altered in mice with multisystem LCH. Consistent with

23 patterns of systemic inflammation in LCH, we found elevated pro-inflammatory cytokines in the

24 brains of *BRAF*V600E^{Scl} chimera, as compared to their wild-type counterparts (**Fig. 3a**, **b**). To

25 measure if systemic inflammation was associated with increased BBB leakage in our model, we

26 intravenously injected LCH animals with the albumin-bound Evans blue dye and measured its

27 extravasation into the brain parenchyma. We found significantly increased dissemination of Evans

28 blue dye throughout the brains of LCH mice, compared to that of control animals, indicative of an

29 altered BBB that enabled the translocation of small molecules (**Fig.3 c, d**). To directly measure an

30 active translocation of blood-derived cytokines, we intravenously injected *BRAF*V600E^{Scl} and

31 *BRAF*wt^{Scl} control animals with a biotinylated version of the inflammatory cytokine interleukin 1 beta

32 (IL-1β) in *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control animals. We used an avidin-bound fluorescent

33 dye to measure the accumulation of translocated IL-1β in the brain parenchyma of injected mice.

34 Importantly, we found a significant increase of extravasated IL-1β in the brain of LCH mice

1 compared to control mice establishing the increased permeability of the BBB in LCH mice (**Fig. 3e-**
2 **g**).

3

4 To further establish the breakdown of BBB in LCH mice, we measured the pericyte coverage of
5 blood vessels in the brains of *BRAF*V600E^{Scl} and *BRAF*wt^{Scl} chimera as a surrogate of BBB integrity
6 (**Fig. 3h**). Accordingly, we documented significantly reduced pericyte coverage of the BBB of
7 *BRAF*V600E^{Scl} chimera relative to *BRAF*wt^{Scl} chimera, indicating a breakdown of the BBB that likely
8 facilitated the extravasation of inflammatory cytokines such as IL-1β and the migration of bone
9 marrow-derived *BRAF*V600E mutated cells into the brain parenchyma (**Fig. 3i**).

10

11 To assess the pathogenic consequence of the BBB breakdown and increased extravasation of
12 inflammatory cytokines and myeloid cells in the brain parenchyma of LCH mice, we measured the
13 behavioral and neurological phenotypes of *BRAF*V600E^{Scl} chimera using a range of behavioral tests
14 (**Fig. 3j**). We evaluated murine behavior in an Open Field Assay and found that *BRAF*V600E^{Scl}
15 chimera performed significantly worse compared to control chimera in most relevant parameters
16 such as increase in resting time (**Fig. 3k**), decreased total distance traveled (**Fig. 3l**) and reduced
17 time in center and a lower median velocity (**Fig. 3m-o**). Using a rotarod assay, we found that
18 *BRAF*V600E^{Scl} chimera have reduced grip strength and a shorter latency to fall compared to WT
19 mice (**Fig. 3p, q**), suggesting profound motor deficit in LCH mice. Because CD11a^{+} macrophages
20 mostly accumulated in the cerebellum, we further focused on motor function assays. Using a
21 footprint assay, we observed a significantly shortened hindlimb and forelimb stride length (**Fig. 3r, s**)
22 and a trend towards a broader hind- and forelimb base (**Fig. 3t, u**). Sporadic cases of unilateral
23 paralysis had also been observed (**Fig. 3v**). Using multiplex immunohistochemistry staining, we also
24 measured Purkinje damage and found a significant loss of Purkinje cells and astrocyte activation in
25 close proximity to *BRAF*V600E-mutated cells in the brain of *BRAF*V600E^{Scl} chimera in line with the
26 behavioral and neurological phenotypes observed in these mice (**Fig. 3w, x**).

27

28 **Accumulation of circulating, *BRAF*V600E^{+} cells is a driver of LCH-like disease and combined**
29 **senolytic / MAPK inhibitor therapy alleviates the disease burden**
30 Bcl-xL is highly expressed in systemic LCH lesions, and we have previously shown that treatment of
31 *BRAF*V600E^{Scl} mice with the senolytic Bcl-xL inhibitor can deplete LCH cells[3,11]. We therefore tested
32 the ability of MAPK pathway inhibition (trametinib [T], MEK inhibitor) and senolytic therapy
33 (navitoclax [N], Bcl-xL inhibitor) to reduce the accumulation of mutant CD11a^{+} macrophages in the
34 brain and the associated neuroinflammation (**Fig. 4a, d**). MAPK pathway inhibition monotherapy has

1 become a mainstay in relapsed and refractory LCH, but fails to eradicate the LCH clone in mice and

2 humans; it is also less effective in LCH-ND, compared to systemic LCH[21,22]. In this study, combining

3 MEK inhibition (T) and Bcl-xL inhibition (N) led to a substantial reduction of LCH cells in the lungs of

4 mice (**Fig. 4b, Figure S3a**). Importantly, we also found that MEK inhibition and Bcl-xL inhibition (NT)

5 led to a substantial reduction of CD11a$^+$ macrophages in the brain parenchyma mice of transgenic

6 *BRAF*V600E^{Scl} mice (**Fig. 4c**). We confirmed a beneficial effect of the NT combination therapy in the

7 *BRAF*V600E^{Scl} chimera model with a significant reduction of pathologically increased liver and

8 spleen weight, which become infiltrated with mutant cells in disseminated LCH (**Fig. 4d-f**). Strikingly,

9 treatment with the NT combination also corrected the behavioral impairment observed in LCH mice

10 with a normalized performance in most aspects of the Open Field Assay (**Fig. 4g-j** and **k,** top and

11 middle rows) which correlated with reduced accumulation of mutant cells in the brains of these mice

12 (**Fig. 4k**, bottom row).

1   **Discussion**

2   LCH-ND is a devastating condition that arises in 10% of patients following the development of

3   systemic LCH. In the most severe cases, patients develop progressive dysarthria, dysmetria, and

4   ataxia that causes significant morbidity and can lead to death[5]. The etiology of LCH-ND has been

5   historically poorly defined. In the past decades, the few brain biopsies studied showed inflammatory

6   cells, but lacked CD207$^+$ cells characteristic of systemic LCH lesions and granulomatous brain

7   lesions[6,7]. LCH-ND was therefore considered a paraneoplastic or autoimmune phenomenon and

8   typically treated with immunomodulatory therapies (e.g., intravenous immune globulin, IVIG).

9   Importantly, we identified *BRAF*V600E$^+$ cells in the brain biopsies of LCH-ND[17]. In fact, in a brain

10 autopsy from a young patient with fatal LCH-ND, we found that >10% of cells in brainstem and

11 cerebellum were *BRAF*V600E$^+$, and anatomic concentration of *BRAF*V600E$^+$ cells mirrored

12 distribution of disease identified by T2 hyperintensity on MRI. Further, histology of LCH-ND biopsy

13 and autopsy specimens characterized the perivascular concentration of *BRAF*V600E$^+$ cells. We also

14 identified *BRAF*V600E$^+$ cells in peripheral blood of patients with LCH-ND (without systemic lesions),

15 but did not identify persistent *BRAF*V600E$^+$ cells in peripheral blood of patients cured of systemic

16 LCH and without LCH-ND[17] (**Fig. 2b**). Similarly, Mass et al. reported the presence of *BRAF*V600E$^+$

17 cells in brain biopsies from patients with LCH and related disorder Erdheim-Chester Disease

18 (ECD)[23]. These findings strongly support a clonal relationship between LCH-ND and systemic LCH.

19 Based on our observations of the presence of circulating *BRAF*V600E$^+$ cells in patients with LCH-ND

20 and perivascular distribution of *BRAF*V600E$^+$ in LCH-ND biopsies, we hypothesized that LCH-ND is

21 caused by circulating, bone marrow-derived myeloid cells clonal with systemic LCH lesion MNPs[17].

22

23 To define the mechanisms of LCH-ND, we evaluated three different mouse models for LCH

24 (*BRAF*V600E^{Scl}, *BRAF*V600E^{Map17}, *BRAF*V600E^{Scl} chimera) in which *BRAF*V600E is post-natally

25 enforced in HSCs. All of these mice developed aggressive systemic LCH-like disease with risk-organ

26 involvement. We found that circulating *BRAF*V600E$^+$ cells infiltrated the brain parenchyma in late-

27 stage disease in all three models, similar to the paradigm in human disease. LCH-ND is typically a

28 late complication of multi-system LCH and typically develops years to decades after the systemic

29 disease has been treated. Recapitulating this sequential pattern and long latency in mouse models is

30 difficult. The advantage and likewise drawback, however, of transgenic mouse models is that the

31 disease burden reflected by the number of circulating cells is higher. In our *BRAF*V600E^{Scl} chimera,

32 roughly 10-20% of all peripheral blood cells expresses the *BRAF*V600E mutation (**Fig 1c**), whereas

33 the burden of circulating cells in human disease varies but is usually in the range of low single-digit

34 percentage, mostly <5%[17]. The higher number of circulating *BRAF*V600E$^+$ cells in *BRAF*V600E^{Scl}

1   mice and *BRAF*V600E*^Scl* chimera then allows a more rapid onset of CNS disease that can be studied

2   before the animals succumb to systemic LCH.

3

4   We found that human and murine brain manifestations in LCH share similar characteristics which

5   include 1) a similar distribution pattern of inflammatory cells in the brain parenchyma 2) the presence

6   of circulating *BRAF*V600E⁺ myeloid cells expressing a senescence transcriptional program, 3) the

7   presence of inflammatory mediators in the brain parenchyma 4) neurological impairment that affects

8   the cerebellum as well as the brain stem. This leads to motor symptoms such as

9   dysdiadochokinesis, ataxia and dysarthria and a reduction of Purkinje cells as reflected by the

10   behavioral assays performed particularly the footprint assay and is in line with clinical observations in

11   human LCH-ND cases.

12

13   Importantly, we found that the accumulation of circulating *BRAF*V600E⁺ cells was associated with a

14   breakdown of the BBB with increased translocation of inflammatory cytokines and infiltration of

15   circulating senescent *BRAF*V600E⁺ myeloid cells into the brain parenchyma. We also show that

16   circulating *BRAF*V600E⁺ myeloid cells differentiated into senescent CD11a⁺ macrophages within the

17   brain parenchyma. It is likely that cellular senescence of circulating *BRAF*V600E⁺ myeloid cells and

18   brain-infiltrating *BRAF*V600E⁺ macrophages contribute to disease progression due to apoptosis

19   resistance and production of senescent associated secretory proteins (SASP) which include

20   inflammatory cytokines such as IL-1, IL-6, and matrix metalloproteinases (MMPs). Inflammation has

21   long been known to disrupt the BBB and contribute to the pathogenesis of ND[24,25]. MMPs in

22   particular have been shown to be secreted by immune cells leading to a degradation of the

23   basement membrane and subsequent disruption of the BBB[26]. Inflammatory cytokines have also

24   been shown to facilitate the migration of myeloid cells into the brain[27]. Importantly, pre-clinical data

25   from LCH mouse models demonstrate that senolytic therapy (e.g., navitoclax), along with MAPK

26   inhibition, may prevent the persistence and differentiation of senescent myeloid cells and

27   subsequent, pathologic neuroinflammation in LCH-ND.

28

29   A recent study reported that enforced expression of *BRAF*V600E in erythromyeloid progenitors in

30   mouse embryos leads to progressive neurodegeneration in a mouse model without systemic LCH-

31   like disease and also identified *BRAF*V600E⁺ cells with a microglia-like phenotype in brain biopsies

32   of patients with neurodegeneration associated with histiocytic disorders[23]. A debate has

33   subsequently developed regarding mechanisms of LCH-ND (and ND associated with related

34   histiocytoses such as ECD) and whether the pathogenic cells invading the brain originate from

1   circulating $BRAF$V600E$^+$ MNP that derived from $BRAF$V600E$^+$ hematopoietic precursors in the bone

2   marrow or from $BRAF$V600E$^+$ microglia that seed the brain during embryonic development.

3   Differentiating these models has significant clinical implications on surveillance and therapeutic

4   strategies to prevent and treat LCH-ND.

5   A bone marrow-derived pathogenesis paradigm supports a treatment goal of molecular negativity in

6   measurable residual disease (MRD), as is typical for malignant hematologic diseases. The ability of

7   post-natal $BRAF$V600E$^+$ myeloid precursors to recapitulate cellular and clinical features of LCH-ND –

8   and the identification of $BRAF$V600E$^+$ PBMC and the perivascular localization of $BRAF$V600E$^+$

9   CXCR4$^+$ myeloid cells in the brain of human LCH-ND – strongly support a hematopoietic origin of

10   cellular drivers of LCH-ND. We previously reported that the extent of disease in LCH is determined

11   by the differentiation state of the myeloid precursors in which the $BRAF$V600E mutation (or

12   alternative activating MAPK pathway mutations) arise[10]. The patterns of disease associated with

13   LCH-ND (e.g., disseminated LCH, lesions in skull base and facial bones, and pituitary involvement[5])

14   may represent $BRAF$V600E in myeloid precursors with potential to develop into both CD207$^+$ DC-like

15   cells (systemic lesions) and monocyte-derived CD11a$^+$ macrophages (LCH-ND). Currently, "cure"

16   with MRD negativity is sometimes achieved by chemotherapy but rarely achieved by MAPK inhibitor

17   treatment alone, even in cases with positive clinical responses[22,28]. Patients with resolution of

18   systemic lesions but persistent $BRAF$V600E$^+$ peripheral blood clone could remain at risk for the

19   development of LCH-ND. Therefore, the newly-described CD11a$^+$ macrophage represents a Trojan

20   horse, and a potential therapeutic target, responsible for trafficking LCH disease to the CNS.

21

22   The mouse models and treatment approaches developed in this study not only transform our

23   understanding of LCH-ND pathophysiology, but also pave the way for future preventive and

24   therapeutic treatment trajectories for LCH-ND. Beyond LCH, MAPK activation in monocyte

25   precursors could be more broadly relevant in driving neuroinflammation in conditions such as

26   infections or age-associated clonal hematopoiesis, where MAPK activation in monocytes from a

27   variety of stimuli may prompt differentiation into senescent CD11a$^+$ macrophages, invasion of the

28   BBB, and neuroinflammation.

29

Acknowledgements

1 **Author contributions**

2 Conceptualization, CMW, FC, OT, SAL, FG, SJR, CAE, MM

3 Methodology, CMW, FC, OT, PH, SB, MM

4 Validation, CMW, FC, OT, JLB, MDP, GRH, PH, LT, BPS, DD, AS,

5 Formal Analysis, CMW, FC, OT, MDP

6 Investigation, CMW, FC, OT, JLB, MDP, GRH, PH, LT, BPS, DD, AS, RF, MB, HL, EMT, JKK, SAL

7 Resources, ZY, JFC, KLM, JLP, SJR, CAE, MM

8 Data Curation, CMW, JLB, MDP

9 Writing – Original Draft, CMW, CAE, MM

10 Writing – Review & Editing, CMW, FC, OT, JLB, MDP, GFH, PH, BPS, MB, SB, KLM, JLP, SJR,
11 CAE, MM

12 Visualization, CMW, OT, GRH, PH

13 Supervision, SJR, CEA, MM

14 Project Administration, CMW, CEA, MM

15 Funding Acquisition, CWM, CEA, MM

16
17
18

1   **Declaration of Interests**
2
3   The authors declare no competing interests.
4

1   **Figure Legends**

2

3   **Figure 1:** Genetic fate-mapping reveals that circulating *BRAF*V600E$^+$ myeloid cells accumulate in

4   the brains of mice with LCH-like disease

5   **a,** experimental setup of *Scl* and *Map17*-based LCH mouse models: Tamoxifen was applied for Cre

6   recombination and mice were then terminally analyzed after 8-16 weeks as indicated. **b,**

7   representative spectral cytometry pseudocolor and histogram plots of microglia (MG), perivascular

8   macrophages (PVM) and CD11a$^+$ macrophages from *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control

9   mice. The abundance of reporter-tagged cells in these populations is displayed in the respective

10   histogram plots. **c,** correlation between percentage of YFP-tagged cells in the peripheral blood and

11   percentage of YFP-tagged cells in the brains of *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control mice

12   (n=7-10). **d,** experimental setup to generate *BRAF*V600E^{Scl} chimera and *BRAF*wt^{Scl} control chimera.

13   **e,** representative spectral cytometry pseudocolor and histogram plots of the brain myeloid cell

14   populations of *BRAF*V600E^{Scl} chimera and *BRAF*wt^{Scl} control chimera. **f,** expression of key lineage

15   markers in the different brain myeloid cell populations of *BRAF*V600E^{Scl} chimera and *BRAF*wt^{Scl}

16   control chimera. **g,** experimental setup of intravascular cell staining to determine vascular vs

17   parenchymal localization of cells: *BRAF*V600E^{Scl} mice were injected with a BV510-conjugated anti-

18   CD45 antibody and were shortly after terminally analyzed (n=4 mice). **h,** Representative spectral

19   cytometry pseudocolor plots of intravenous CD45 staining for each myeloid cell population.

20

21   **Figure 2:** LCH mice with brain-infiltrating *BRAF*V600E-mutated cells share phenotypic and

22   transcriptional characteristics with human LCH-ND

23   **a,** manifestation of LCH-ND in a schematic human brain and **b,** quantification of *BRAF*V600E

24   transcripts from this specimen. **c,** visualization of the extent to which mouse brains are affected by

25   infiltration with *BRAF*V600E-mutated cells based on the quantification from different brain regions

26   depicted in **d** (n=4 mice). **e,** Representative IHC images from the brain of a *BRAF*wt^{Scl} chimera on

27   the left and *BRAF*V600E^{Scl} chimera on the right stained for YFP-tagged, BM-derived cells marked

28   with yellow arrows. In *BRAF*wt^{Scl} chimera, these cells are lineage-traced unmutated cells (left) and in

29   *BRAF*V600E^{Scl} chimera, these stained cells are *BRAF*V600E$^+$ cells (right). **f-k,** CD11a$^+$ macrophages

30   (**f**), peripheral blood monocytes (**g**) as well as microglia (**h**) from *BRAF*wt^{Scl} and *BRAF*V600E^{Scl} mice

31   were subjected to bulk RNA sequencing from each 10 mice per group (pooled). Expression profiles

32   of CD11a$^+$ macrophages (**f**)**,** monocytes (**g**) and microglia (**h**) from *BRAF*wt^{Scl} mice were compared

33   with those from *BRAF*V600E^{Scl} mice in **i** by analysis of the deviance of transcriptomes showing that

34   the transcriptomic remodeling was strongest in CD11a$^+$ macrophages. While monocytes and

1   CD11a$^+$ macrophages in *BRAF*V600E^{Scl} mice are *BRAF*V600E mutated, microglia is unmutated in

2   *BRAF*V600E^{Scl} mice. **j**, the transcriptional remodeling in CD11a$^+$ macrophages was driven by

3   senescence-associated genes as well as Matrix Metalloproteinases and integrins. **k**, comparative

4   analysis of gene expression of key lineage markers in mouse CD11a$^+$ macrophages, peripheral

5   blood monocytes and microglia. **l,** comparison of these lineage markers between a human bulk RNA

6   sequencing data set from an LCH-ND case and human myeloid cells from a healthy brain

7   demonstrating an enrichment for CD11a$^+$ macrophage-defining *Itgal* (encoding integrin alpha L

8   chain, CD11a) as well as *Itga4* (encoding integrin alpha 4 chain, CD49d). **m,** cross-species

9   comparison of mouse *BRAF*V600E$^+$ CD11a$^+$ macrophages and human LCH-ND material showing

10   that 57.5% of the genes were enriched in mouse and human LCH material. Data in **d** are shown as

11   means ± s.e.m, ****p<0.0001. Abbreviations: LCH-ND: neurodegenerative LCH, wt: wild-type, VE:

12   *BRAF*V600E

13

14   **Figure 3:** *BRAF*V600E^{Scl} chimera have a compromised BBB and exhibit behavioral and neurologic

15   abnormalities

16   **a,** experimental setup to quantify inflammatory cytokines from brain lysates from *BRAF*V600E^{Scl} and

17   *BRAF*wt^{Scl} mice. **b**, multiplexed cytokine detection in the brains of *BRAF*V600E^{Scl} and *BRAF*wt^{Scl}

18   control mice (n=3 mice per group). **c**, experimental setup of an Evans Blue-based assay to quantify

19   the permeability of the BBB for small molecules showing increased permeability in *BRAF*V600E^{Scl}

20   mice (**d**, n=4-5 mice per group). **e**, experimental setup to assess and quantify the transition of

21   biotinylated IL-1β into the brain of *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control mice. **f**, representative

22   images of IL-1β (cyan) and Collagen IV (red) showing a scattered perivascular signal derived from

23   biotinylated IL-1β that can be detected in *BRAF*V600E^{Scl} mice but not *BRAF*wt^{Scl} control mice (n=3-4

24   mice per group). **g**, quantification of IL-1β-derived fluorescent signal shows a significant increase in

25   extravasation of biotinylated IL-1β into the brain parenchyma in *BRAF*V600E^{Scl} mice compared to

26   *BRAF*wt^{Scl} mice. **h**, experimental setup to assess the pericyte coverage of brain vessels from

27   *BRAF*V600E^{Scl} and *BRAF*wt^{Scl} chimera. **i**, *BRAF*V600E^{Scl} chimera have a decreased blood vessel

28   coverage with pericytes compared to *BRAF*wt^{Scl} chimera (n=3-4 mice per group). **j**, experimental

29   setup for behavioral assays and histological studies for **k-x**. **k-o**, performance of *BRAF*V600E^{Scl}

30   chimera (VE) and *BRAF*wt^{Scl} chimera (WT) in an open field setup showing a deteriorated

31   performance with reduced resting time (**k**), distance traveled (**l**), time in center (**m**) and median

32   velocity (**n**) summarized in the activity plots, **o** (n=7 mice per group). Grip strength (**p**) and latency to

33   fall (**q**) quantification of *BRAF*V600E^{Scl} and *BRAF*wt^{Scl} chimera in a Rotarod assay (n=7 mice per

34   group). **r-v**, footprint analysis of Hindlimb and Forelimb Stride **(r, s)** as well as Hindlimb and Forelimb

1   base as signs of a motor deficit in $BRAF$V600E^{Scl} chimera (**t, u**, n=6-10 mice per group). **v,**
2   representative case of unilateral paralysis in a $BRAF$V600E^{Scl} chimeric mouse compared to a
3   $BRAF$wt^{Scl} mouse; hind paws painted with blue and front paws painted with red ink. **w,** quantification
4   of Purkinje cells in $BRAF$V600E^{Scl} chimera and $BRAF$wt^{Scl} chimera (n=4 mice per group). **x**,
5   representative images of multiplex immunohistochemistry of the brains of $BRAF$V600E^{Scl} chimera
6   staining for activated astrocytes (anti-GFAP, left), $BRAF$V600E-mutated cells (anti-YFP, middle) and
7   showing co-localization (overlay, right). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n.s. = not
8   significant. Data are shown as means ± s.e.m. Abbreviations: r.o.: retro orbital, GFAP: Glial Fibrillary
9   Acidic Protein.

10

11   **Figure 4:** Accumulation of circulating, $BRAF$V600E^{+} cells is a driver of LCH-like disease and
12   combined senolytic / MAPK inhibitor therapy alleviates the disease burden
13   **a,** experimental setup for *in vivo* drug treatment of $BRAF$wt^{Scl} mice and $BRAF$V600E^{Scl} mice with
14   Navitoclax/Trametinib (NT) or vehicle control. **b,** percentage of YFP^{+} cells in the lungs of $BRAF$wt^{Scl}
15   (WT) and $BRAF$V600E^{Scl} (VE) mice receiving vehicle or Navitoclax/Trametinib (NT) treatment
16   analyzed by spectral cytometry (n= 5-6 per group). **c,** percentage of CD11a^{+} macrophages in the
17   brains of $BRAF$wt^{Scl} (WT) and $BRAF$V600E^{Scl} (VE) mice receiving vehicle or NT combination
18   treatment (n=5-6 per group). **d**, experimental setup for *in vivo* drug treatment of $BRAF$wt^{Scl} chimera
19   and $BRAF$V600E^{Scl} chimera with Navitoclax/Trametinib (NT) or vehicle control. **e-f,** quantification of
20   the weight of the spleens (**e**) and the livers (**f**) of $BRAF$wt^{Scl} (WT) and $BRAF$V600E^{Scl} (VE) chimera
21   receiving vehicle or NT treatment (n=3-4 mice per group). **g-j** Open Field assessment of vehicle- or
22   NT-treated $BRAF$wt^{Scl} (WT) and $BRAF$V600E^{Scl} (VE) chimera with quantification of the resting time
23   **(g)**, distance travelled **(h)**, time in the center **(i)** and mouse median velocity. **k,** movement heatmap
24   (top row) and path traveled (middle row) in the Open Field assessment with paired anti-YFP IHC
25   from cerebellar regions (bottom row) of the respective mice. *p<0.05, **p<0.01, ***p<0.001,
26   ****p<0.0001, n.s. = not significant. Data are shown as means ± s.e.m. Abbreviations: NT: Navitoclax
27   / Trametinib, IHC: Immunohistochemistry

28

29

1   **STAR Methods**

2

3   **Mice**

4   *BRAF*V600E*[HSC-Scl-CreERT]*xR26*[YFP/-]* mice (*BRAF*V600E*[Scl]* mice) and *BRAF*wt*[HSC-Scl-CreERT]*xR26*[YFP/-]* mice

5   (*BRAF*wt*[Scl]* control mice) were generated as described previously[3]. To induce recombination in these

6   mice, 5 doses of tamoxifen were given on 5 consecutive days (5mg, 2mg, 2mg, 1mg, 1mg) as

7   previously described[29]. *BRAF*V600E*[Scl]* mice and *BRAF*wt*[Scl]* control mice were terminally analyzed

8   between week 8 and 12 post tamoxifen induction. *BRAF*V600E*[Map17-CreERT]*xR26*[tdTomato/-]* mice

9   (*BRAF*V600E*[Map17]* mice) and *BRAF*wt*[Map17-CreERT]*xR26*[tdTomato/-]* mice (*BRAF*wt*[Map17]* control mice) were

10   generated by crossing *Map17[creER/+]R26tdTomato[+/+]* (*Pdzk1ip1-creER R26tdTomato[+/+]*)[15,20] mice to

11   *BRAF*V600E*[ca/WT]* mice. To induce recombination in *BRAF*V600E*[Map17]* mice and *BRAF*wt*[Map17]* control

12   mice, 1 dose of 5mg tamoxifen was given as previously described[15,20]. *BRAF*V600E*[Map17]* mice and

13   *BRAF*wt*[Map17]* control mice were terminally analyzed between week 12 and 16 post tamoxifen

14   induction. BM chimera were generated by transplanting 5×10^6 total BM cells from *BRAF*V600E*[Scl]*

15   mice or *BRAF*wt*[Scl]* control mice into congenic CD45.1 WT host mice (*BRAF*V600E*[Scl]* chimera and

16   *BRAF*wt*[Scl]* control chimera). Host mice were irradiated with twice 5.5Gy 6 hours apart with a lead

17   shield protecting the head of the host mice in analogy to a previous report[16]. To induce

18   recombination in *BRAF*V600E*[Scl]* chimera and *BRAF*wt*[Scl]* control chimera, 2 doses of tamoxifen 2mg

19   were given 1 week apart not earlier than 4 weeks after transplantation. Chimera were terminally

20   analyzed between week 12 and 20 after tamoxifen induction. Ethical approval for mouse

21   experiments was obtained by the Internal Animal Care and Use Committee (IACUC) at the Mount

22   Sinai Hospital.

23

24   **Brain macrophage isolation**

25   Brain macrophages were isolated as described previously[14]. Mice were anesthetized with

26   Ketamine/Xylazine and upon areflexia transcardially perfused with PBS. Brains were extracted, cut

27   into small pieces and digested with Collagenase IV 0.2 mg/mL (Sigma, C5138-1G) and DNAse-1

28   0.05mg/mL (Sigma, DN25-1G) in RPMI containing 10% FCS [30] for 30 min at 37°C. Digested brains

29   were passed through a 70-μm cell strainer and incubated with magnetic anti-CD45 microbeads

30   (Miltenyi Biotec, #130-052-301) according to the manufacturer's instructions. CD45$^+$ cells were

31   isolated using two consecutive LS columns (Miltenyi Biotec, #130-042-401) per brain and subjected

32   to downstream analyses.

33

34

1

Intravascular staining for discrimination of vascular vs parenchymal myeloid cells

Discrimination of intravascular vs extravascular myeloid cells was performed in analogy to published protocols[31,32]. Mice were anesthetized with Ketamine/Xylazine and 10µl of an anti-mouse CD45 antibody conjugated to BV510 were injected intravenously in a 100µl PBS. 10 minutes later, mice were anaesthetized and perfused with PBS. Brain macrophages were then extracted as described above and stained with respective antibodies containing an anti-mouse CD45 antibody conjugated to AF700.

Spectral cytometry

Brain macrophage single cell suspensions were stained with a fixable blue dead cell stain kit (ThermoFisher Scientific, L-23105) in PBS for 15min on ice. After one washing cycle in cytometry buffer (PBS containing 10% BSA and 2mM EDTA), each cell sample was resuspended in 50µl of cytometry buffer containing the respective antibodies and complemented with 5µl of Super Bright Complete Staining Buffer (ThermoFisher Scientific, SB-4401-75). Samples were acquired on a Cytek® Aurora full spectrum cytometer (Configuration: 5 Laser - 16UV-16V-14B-10YG-8R). Autofluorescence detection and extraction was applied during unmixing using Cytek® SpectroFlo® v2.2.0.3 software (Cytek Biosciences, Fremont, CA, USA). Unmixed .fcs files were then analyzed with FlowJo Version 10 (Becton Dickinson, Franklin Lakes, NJ, USA). Gating strategies are displayed in **Fig. S2** and **Fig. S3**. Conditions for the respective antibodies are listed in **Table S1**.

Cell sorting

Brain macrophage single-cell suspension and cell staining was performed as described above. Brain samples were then sorted on a Cytek® Aurora CS full spectrum cell sorter (Configuration: 5 Laser - 16UV-16V-14B-10YG-8R) with autofluorescence detection and extraction applied during unmixing (Cytek Biosciences, Fremont, CA, USA). The instrument was set up using a 100µm nozzle at 18.3psi using Single Cell sort mode. Cells were sorted into RNA lysis buffer in 1.5ml tubes. Sorted brain macrophage populations were then subjected to Ultra-low-input RNA sequencing. Conditions for the respective antibodies are listed in **Table S1**.

Ultra-low-input RNA-sequencing

RNA extraction, library preparation, sequencing and analysis were completed at Azenta Life Science (South Plainfield, NJ) as follows:

RNA Extraction

1 Total RNA was extracted using Qiagen RNeasy Plus Mini kit following manufacturer's instructions

2 (Qiagen, Hilden, Germany). Extracted RNA samples were quantified using Qubit 2.0 Fluorometer

3 (Life Technologies, Carlsbad, CA, USA) and RNA integrity was checked using Agilent TapeStation

4 4200 (Agilent Technologies, Palo Alto, CA, USA).

5 Library Preparation

6 Ultra-low input RNA sequencing library was prepared by using SMART-Seq HT kit for full-length

7 cDNA synthesis and amplification (Takara, San Jose, CA, USA), and Illumina Nextera XT (Illumina,

8 San Diego, CA, USA) library was used for sequencing library preparation. Briefly, cDNA was

9 fragmented, and adaptor was added using Transposase, followed by limited-cycle PCR to enrich and

10 add index to the cDNA fragments. The sequencing library was validated on the Agilent TapeStation

11 (Agilent Technologies, Palo Alto, CA, USA), and quantified by using Qubit 2.0 Fluorometer

12 (ThermoFisher Scientific, Waltham, MA, USA) as well as by quantitative PCR (KAPA Biosystems,

13 Wilmington, MA, USA).

14 Sequencing

15 The sequencing libraries were multiplexed and clustered onto a flowcell. After clustering, the flowcell

16 was loaded onto the Illumina HiSeq instrument according to manufacturer's instructions. The

17 samples were sequenced using a 2x150bp Paired End (PE) configuration. Image analysis and base

18 calling were conducted by the HiSeq Control Software (HCS). Raw sequence data (.bcl files)

19 generated from Illumina HiSeq was converted into fastq files and de-multiplexed using Illumina

20 bcl2fastq 2.20 software. One mis- match was allowed for index sequence identification. After

21 investigating the quality of the raw data, sequence reads were trimmed to remove possible adapter

22 sequences and nucleotides with poor quality using Trimmomatic v.0.36. The trimmed reads were

23 mapped to the Mus musculus reference genome available on ENSEMBL using the STAR aligner

24 v.2.5.2b. BAM files were generated as a result of this step. Unique gene hit counts were calculated

25 by using feature Counts from the Subread package v.1.5.2. Only unique reads that fell within exon

26 regions were counted. After extraction of gene hit counts, the gene hit counts table was used for

27 downstream differential expression analysis.

28 Analysis

29 Gene expression was computed as normalized transcript counts per million for individual samples to

30 control for transcript sequencing variability across runs. To assess gene expression patterns across

31 species, homologous genes between mice and humans were identified in the libraries generated for

32 this study and for prior published work (GSE 73721 and GSE 74442)[18,33]. Respective datasets were

33 then subsetted for these homologous genes across samples to compute log normalized gene

34 expression as an integrated dataset. To assess transcriptomic differences driven by induction of the

1   *BRAF*V600E mutation in hematopoietic cells, a deviance score – defined as the orthogonal distance

2   of individual genes from the line of equality on a Cartesian plane, representative of concordance in

3   mRNA expression – was generated to compute a quantitative description for transcriptomic

4   remodeling.

5

6   **Immunohistochemistry and Multiplexed immunohistochemical consecutive staining on a**

7   **single slide**

8   Mice were anesthetized with Ketamine/Xylazine as previously described and upon areflexia

9   transcardially perfused with PBS followed by 4% PFA. Brains were extracted and post-fixed in 4%

10 PFA overnight and embedded in paraffin. Multiplexed immunohistochemical consecutive staining on

11 a single slide (MICSSS) was performed as described previously[34]. Conditions for the respective

12 antibodies are listed in **Table S2**.

13

14 **Luminex® multiplexed protein quantification from mouse brains**

15 Brain tissue of perfused mice was dissociated with Pistil A and B and then lysed in ProcartaPlex™

16 Cell Lysis buffer (ThermoFisher Scientific, EPX-999-000) with Halt™ Protease Inhibitor Cocktail

17 (ThermoFisher Scientific, #78430). Samples were spun down at 20.000xg for 10 minutes.

18 Supernatants were frozen at -80°C until further processing. Samples were run on the FlexMap3D

19 Luminex™ machine according to the manufacturer's recommendations using the following Millipore

20 panels: MKI2MAG-94K, MMMP1MAG-79K, MHSTCMAG-70KPXBK, MMMP2MAG-79K (Millipore,

21 Burlington, MA, USA).

22

23 **Evans blue assay**

24 *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control mice were intravenously injected with 6µl/g body weight

25 of Evans Blue 2% in 0.9% saline. 16 hours later, animals were anesthetized with Ketamine /

26 Xylazine and transcardially perfused with 25ml of PBS. Brains were then weighed and 400µl of

27 dimethylformamide was added to the 1.5ml tube containing the brain and dissociated. Brains were

28 incubated at 55°C for 48h and vortexed once daily. Samples were then spun down at 21,000g for

29 30min and supernatant was analyzed on a photometer with an excitation of 620nm and Emission of

30 680nm with an appropriate control standard curve.

31

32 **Pericyte coverage**

33 Brain blood vessel coverage with pericytes was investigated as described previously[35]. Mice were

34 perfused with PBS followed by 4% PFA using a gravity perfusion approach (20cm gradient and

1.2mm tube diameter). Brains were post fixed overnight in 4% PFA and then cut on a vibratome in 60μm thick sections. Free-floating tissue sections were permeabilized overnight in permeabilization buffer (1% BSA, 2% Triton-X100 in PBS) at 4°C. Primary antibodies directed against Collagen IV (Bio-Rad, #2150-1470, 1:300) and CD13 (R&D Systems, AF2335, 1:100) were incubated for 48 hours followed by secondary antibodies (Jackson Immuno Research Cy5™-conjugated AffiniPure Donkey Anti-Goat IgG #705-175-147 and DyLight™488 AffiniPure Donkey Anti-Rabbit IgG #711-485-152, dilution 1:300) for 24 hours. Tissue sections were mounted using Molecular Probes ProLong Gold Antifade Mountant (ThermoFisher Scientific, #P36930). Conditions for the respective antibodies are also listed in **Table S3** and **4**.

Quantification of vessel pericyte coverage

Images of immune-fluorescently labeled sections were acquired by Zeiss LSM780 confocal laser scanning microscope with a 20X objective (Zeiss, Oberkochen, Germany). Pericyte coverage was calculated using the area measurement tool in Fiji. The area of CD13 and Collagen IV signal was measured on binary images in 6 ROIs, 100 x 100 μm each, in sagittal brain section. Coverage was calculated as the percentage of CD13 positive area over the Collagen IV positive area. The Collagen IV area was taken arbitrarily as 100% and the CD13 positive area was expressed as a percentage normalized to the Collagen IV area.

Biotinylation.

Biotinylation of recombinant IL-1β (R&D Systems, 201-LB-025/CF) was performed using the EZ-Link™ Sulfo-NHS-Biotin kit according to the manufacturer's instructions (ThermoFisher Scientific, #A39256). Biotinylated IL-1β was separated from unbound biotin using Pierce™ C18 Spin Columns, 7K MWCO, (ThermoFisher Scientific, #89870), which recovers proteins and macromolecules larger than 7kDa. 100μl of biotinylated IL-1β was injected retro-orbitally into anaesthetized mice at a concentration of 250ng/ml. After 2 hours of circulation, mice were euthanized and perfused with ice cold PBS followed by 4% PFA. Brain tissue processing and imaging was performed as described in the Pericyte coverage section. Biotin was visualized using the Oregon Green® 488 conjugate of NeutrAvidin® biotin-binding protein (ThermoFisher Scientific, #A6374). Counterstaining was performed using rabbit anti-Collagen IV (1:300, Bio-Rad, #2150-1470). Conditions for the respective antibodies are also listed in **Table S3** and **4**.

Open Field Assay

1 *BRAF*V600E*Scl* chimera and *BRAF*wt*Scl* chimera were studied for abnormal behavior in an Open Field

2 assay. Therefore, movement of mice was tracked in an open field chamber for 60 minutes during the

3 night cycle after acclimatization to red light for one hour. Data were analyzed using the proprietary

4 software of the Open Field chambers (Omnitech Electronics, Fusion 5.6).

5

6 **Grip strength analysis**

7 *BRAF*V600E*Scl* chimera and *BRAF*wt*Scl* control chimera were tested for grip strength using a grip

8 strength meter (Biosep, Bio-GS3) as suggested by the manufacturer. Mice were trained on the setup

9 before grip strength was assess in 3 consecutive rounds including appropriate breaks between

10 sessions. Mean values of the peak grip force of each mouse were used for statistical analysis.

11

12 **Rotarod Assay**

13 *BRAF*V600E*Scl* chimera and *BRAF*wt*Scl* chimera were evaluated for ataxia using an accelerating

14 rotating rod (Rotarod) setup[36]. The animals were placed on the rotating rod an acceleration from 4 to

15 40rpm was initiated. Latency to fall from the rod was recorded after training runs. In total 3 recorded

16 sessions were analyzed and mean latency to fall plotted.

17

18 **Footprint analysis**

19 *BRAF*V600E*Scl* chimera and *BRAF*wt*Scl* control chimera were investigated for cerebellar ataxia using

20 a footprint assay as previously described[37].

21

22 ***In vivo* drug treatment**

23 *BRAF*V600E*Scl* mice and *BRAF*wt*Scl* control mice as well as *BRAF*V600E*Scl* chimera and *BRAF*wt*Scl*

24 control chimera were treated with Navitoclax at a dose of 50mg/kg daily by oral gavage (ApexBio,

25 #A3007)[3] in combination with Trametinib 1mg/kg daily intraperitoneally (i.p.) (Selleck Chemicals,

26 #S2673)[38] for 8 weeks before terminal analysis.

27

28 **Data availability**

29 Datasets supporting the findings presented in this study are available from the corresponding author

30 upon reasonable request. Any data that can be shared will be released via a material transfer

31 agreement. Bulk RNA-seq data obtained from mouse brain macrophages will be made available

32 upon request.

33

34

1

2

3   **Statistical analysis**

4   Statistical significance between groups was determined by unpaired Student's t-test or one-sided

5   ANOVA; data are displayed as means ± s.e.m. Statistical analysis was done with GraphPad Prism

6   v.9.3.

7

1 **Supplementary Figure Legends:**

2 **Figure S1:** LCH phenotype of *BRAF*V600E^{Map17} mice and *BRAF*V600E^{Scl} chimera in comparison to

3 respective control mice.

4 **a,** representative H&E images of lung tissue from a *BRAF*V600E^{Map17} (right) mouse and a

5 *BRAF*wt^{Map17} control mouse (left) showing typical granulomatous lesions in this LCH mouse model

6 12-16 weeks post Tamoxifen injection **b**, representative H&E images of liver tissue of these mice

7 showing immune cell infiltrates in *BRAF*V600E^{Map17} (right) mice but not in *BRAF*wt^{Map17} control mice

8 (left). **c**, representative IHC staining of the *BRAF*V600E reporter tdTomato in the brain tissue of

9 *BRAF*V600E^{Map17} revealing a diffuse infiltration of the brains of *BRAF*V600E^{Map17} mice (right panel)

10 but not *BRAF*wt^{Map17} control mice 12-16 weeks post Tamoxifen injection (left panel). **d**,

11 representative spectral cytometry pseudocolor plots of brain microglia (MG), perivascular

12 macrophages (PVM) and CD11a$^+$ macrophages of *BRAF*V600E^{Map17} mice and *BRAF*wt^{Map17} control

13 mice confirming the abundance of the pathognomonic CD11a$^+$ macrophage population in the brains

14 of *BRAF*V600E^{Map17} mice. **e**, representative H&E stain of lungs from *BRAF*V600E^{Scl} chimera (right)

15 and *BRAF*wt^{Scl} control chimera (left) showing typical granulomatous LCH-like lesions in

16 *BRAF*V600E^{Scl} chimera. **f**, representative IHC staining of the reporter protein YFP in the lungs of

17 *BRAF*V600E^{Scl} chimera demonstrating that *BRAF*V600E-mutated cells accumulate in granulomatous

18 lesions in the lungs of *BRAF*V600E^{Scl} chimera (right) while scattered YFP-tagged cells can be

19 detected in the lungs of *BRAF*wt^{Scl} control chimera (left). **g**, donor chimerism in *BRAF*V600E^{Scl}

20 chimera and *BRAF*wt^{Scl} control chimera at terminal analysis (CD45.2 as percent of total CD45)

21 showing comparable chimerism between *BRAF*V600E^{Scl} chimera and *BRAF*wt^{Scl} control chimera.

22

23 **Figure S2:** Gating Strategies

24 **a,** gating strategy for brain myeloid cells from *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control mice and

25 *BRAF*V600E^{Scl} chimera and *BRAF*wt^{Scl} control chimera. **b,** gating strategy for peripheral blood cells

26 in *BRAF*V600E^{Scl} chimera and *BRAF*wt^{Scl} control chimera.

27

28 **Figure S3:** Gating Strategies

29 **a**, gating strategy for lung immune cells from *BRAF*V600E^{Scl} mice and *BRAF*wt^{Scl} control mice.

30

31

32

33

34

1 **Supplementary Tables:**

2 **Table S1 Antibodies used for Spectral Cytometry**

Antigen	Reactivity	Clone	Host	Conjugate	Company	Order number
CD4	mouse	rat	GK1.5	BV750	biolegend	100467
CD11b	mouse/human	rat	M1/70	CD11b	biolegend	101209
CD45	mouse	rat	30-F11	AF700	biolegend	103127
CD45	mouse	rat	30-F11	BV510	biolegend	103137
CD45.1	mouse	mouse	A20	PE	biolegend	110707
MHCII	mouse	rat	M5/114.15.2	BV711	biolegend	107643
Ly-6C	mouse	rat	HK1.4	BV785	biolegend	128041
CD8a	mouse	mouse	QA17A07	BV421	biolegend	155010
Ly-6G	mouse	rat	1A8	BUB805	BD Biosciences	741994
B220	mouse	rat	RA3-6B2	BV570	biolegend	103237
CD11a	mouse	rat	M17/4	PerCP/Cy5.5	biolegend	101123
CD206	mouse	rat	C068C2	PE/Cy7	biolegend	141720
F4/80	mouse	rat	BM8	efluor450	ThermoFisher	48-4801-82
F4/80	mouse	rat	BM8	APC-Fire750	biolegend	123151
F4/80	mouse	rat	BM8	BV605	biolegend	123133

3
4 **Table S2 Antibodies used for Immunohistochemistry**

Antigen	Reactivity	Clone	Host	AG retr	Dilution	Incubation	Company	Order number
Calbindin-1	mouse	Polyclonal	Mouse	pH 9	1500	1h RT	Proteintech	14479-1
YFP GFP	n/a	JL8	Mouse	pH 9	200	4°C o/n	Takara Bio	632381
tdTomato RFP	n/a	Polyclonal	Mouse	pH 9	200	1h RT	Takara Bio	632496
GFAP	mouse/hu	Polyclonal	Rabbit	pH 9	300	1h RT	Agilent	Z033429-2

5

6 **Table S3 Antibodies used for Immunoflourescence**

Antigen	Reactivity	Clone	Host	Dilution	Incubation	Company	Order number
Aminopeptidase N / CD13	Mouse	Polyclonal	goat	100	48h	R&D Systems	AF2335
Collagen IV	Mouse	Polyclonal	rabbit	300	48h	Bio-Rad	2150-1470

7

8

1 **Table S4 secondary antibodies / dyes Immunofluorescence**

| reactivity	clone	host	Con-jugate	Dilution	Incu-bation	company	order no
goat	Poly-clonal	Donkey	Cy5	400	24h	Jackson Immuno Research	#705-175-147
rabbit	Poly-clonal	Donkey	AF488	400	24h	Jackson Immuno Research	#711-485-152
Biotin	n/a	n/a	AF488	300	24h	Thermofisher	#A6374

2

3

References

1. Allen, C.E., Flores, R., Rauch, R., Dauser, R., Murray, J.C., Puccetti, D., Hsu, D.A., Sondel, P., Hetherington, M., Goldman, S., et al. (2010). Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer *54*, 416–423. 10.1002/pbc.22326.

2. Héritier, S., Barkaoui, M., Miron, J., Thomas, C., Moshous, D., Lambilliotte, A., Mazingue, F., Kebaili, K., Jeziorski, E., Plat, G., et al. (2018). Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Brit J Haematol *183*, 608–617. 10.1111/bjh.15577.

3. Bigenwald, C., Berichel, J.L., Wilk, C.M., Chakraborty, R., Chen, S.T., Tabachnikova, A., Mancusi, R., Abhyankar, H., Casanova-Acebes, M., Laface, I., et al. (2021). BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med, 1–11. 10.1038/s41591-021-01304-x.

4. Allen, C.E., Merad, M., and McClain, K.L. (2018). Langerhans-Cell Histiocytosis. New Engl J Medicine *379*, 856–868. 10.1056/nejmra1607548.

5. Yeh, E.A., Greenberg, J., Abla, O., Longoni, G., Diamond, E., Hermiston, M., Tran, B., Rodriguez-Galindo, C., Allen, C.E., McClain, K.L., et al. (2018). Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer *65*, e26784. 10.1002/pbc.26784.

6. Grois, N., Prayer, D., Prosch, H., and Lassmann, H. (2005). Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain *128*, 829–838. 10.1093/brain/awh403.

7. Grois, N., Tsunematsu, Y., Barkovich, A.J., and Favara, B.E. (1994). Central nervous system disease in Langerhans cell histiocytosis. Br J Cancer Suppl *23*, S24-8.

8. Idbaih, A., Donadieu, J., Barthez, M.A., Geissmann, F., Bertrand, Y., Hermine, O., Brugières, L., Genereau, T., Thomas, C., and Hoang□Xuan, K. (2004). Retinoic acid therapy in "degenerative□like" neuro□langerhans cell histiocytosis: A prospective pilot study. Pediatr Blood Cancer *43*, 55–58. 10.1002/pbc.20040.

9. (JLSG), J.L.S.G., Imashuku, S., Fujita, N., Shioda, Y., Noma, H., Seto, S., Minato, T., Sakashita, K., Ito, N., Kobayashi, R., et al. (2015). Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int J Hematol *101*, 191–197. 10.1007/s12185-014-1717-5.

10. Berres, M.-L., Lim, K.P.H., Peters, T., Price, J., Takizawa, H., Salmon, H., Idoyaga, J., Ruzo, A., Lupo, P.J., Hicks, M.J., et al. (2014). BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groupsLCH: neoplasia arising from myeloid precursors. J Exp Medicine *211*, 669–683. 10.1084/jem.20130977.

11. Hogstad, B., Berres, M.-L., Chakraborty, R., Tang, J., Bigenwald, C., Serasinghe, M., Lim, K.P.H., Lin, H., Man, T.-K., Remark, R., et al. (2018). RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med *215*, 319–336. 10.1084/jem.20161881.

1 12. McClain, K.L., Bigenwald, C., Collin, M., Haroche, J., Marsh, R.A., Merad, M., Picarsic, J., Ribeiro, K.B.,
2 and Allen, C.E. (2021). Histiocytic disorders. Nat Rev Dis Primers *7*, 73. 10.1038/s41572-021-00307-9.

3 13. Paolicelli, R.C., Sierra, A., Stevens, B., Tremblay, M.-E., Aguzzi, A., Ajami, B., Amit, I., Audinat, E.,
4 Bechmann, I., Bennett, M., et al. (2022). Microglia states and nomenclature: A field at its crossroads. Neuron
5 *110*, 3458–3483. 10.1016/j.neuron.2022.10.020.

6 14. Silvin, A., Uderhardt, S., Piot, C., Mesquita, S.D., Yang, K., Geirsdottir, L., Mulder, K., Eyal, D., Liu, Z.,
7 Bridlance, C., et al. (2022). Dual ontogeny of disease-associated microglia and disease inflammatory
8 macrophages in aging and neurodegeneration. Immunity. 10.1016/j.immuni.2022.07.004.

9 15. Sawai, C.M., Babovic, S., Upadhaya, S., Knapp, D.J.H.F., Lavin, Y., Lau, C.M., Goloborodko, A., Feng,
10 J., Fujisaki, J., Ding, L., et al. (2016). Hematopoietic Stem Cells Are the Major Source of Multilineage
11 Hematopoiesis in Adult Animals. Immunity *45*, 597–609. 10.1016/j.immuni.2016.08.007.

12 16. Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.-K., Mack, M., Heikenwalder, M., Brück,
13 W., Priller, J., and Prinz, M. (2007). Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only
14 under defined host conditions. Nat Neurosci *10*, 1544–1553. 10.1038/nn2015.

15 17. McClain, K.L., Picarsic, J., Chakraborty, R., Zinn, D., Lin, H., Abhyankar, H., Scull, B., Shih, A., Lim,
16 K.P.H., Eckstein, O., et al. (2018). CNS Langerhans cell histiocytosis: Common hematopoietic origin for
17 LCH-associated neurodegeneration and mass lesions: Hematopoietic Origin of LCH-ND. Cancer *124*, 2607–
18 2620. 10.1002/cncr.31348.

19 18. Diamond, E.L., Durham, B.H., Haroche, J., Yao, Z., Ma, J., Parikh, S.A., Wang, Z., Choi, J., Kim, E.,
20 Cohen-Aubart, F., et al. (2016). Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
21 Cancer Discov *6*, 154–165. 10.1158/2159-8290.cd-15-0913.

22 19. Maier, B., Leader, A.M., Chen, S.T., Tung, N., Chang, C., LeBerichel, J., Chudnovskiy, A., Maskey, S.,
23 Walker, L., Finnigan, J.P., et al. (2020). A conserved dendritic-cell regulatory program limits antitumour
24 immunity. Nature *580*, 257–262. 10.1038/s41586-020-2134-y.

25 20. Casanova-Acebes, M., Dalla, E., Leader, A.M., LeBerichel, J., Nikolic, J., Morales, B.M., Brown, M.,
26 Chang, C., Troncoso, L., Chen, S.T., et al. (2021). Tissue-resident macrophages provide a pro-tumorigenic
27 niche to early NSCLC cells. Nature, 1–7. 10.1038/s41586-021-03651-8.

28 21. Aubart, F.C., Emile, J.-F., Carrat, F., Charlotte, F., Benameur, N., Donadieu, J., Maksud, P., Idbaih, A.,
29 Barete, S., Hoang-Xuan, K., et al. (2017). Targeted therapies in 54 patients with Erdheim-Chester disease,
30 including follow-up after interruption (the LOVE study). Blood *130*, 1377–1380. 10.1182/blood-2017-03-
31 771873.

32 22. Eckstein, O.S., Visser, J., Rodriguez-Galindo, C., Allen, C.E., and Group, N.-L.S. (2019). Clinical
33 responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway
34 inhibition. Blood *133*, 1691–1694. 10.1182/blood-2018-10-878363.

35 23. Mass, E., Jacome-Galarza, C.E., Blank, T., Lazarov, T., Durham, B.H., Ozkaya, N., Pastore, A.,
36 Schwabenland, M., Chung, Y.R., Rosenblum, M.K., et al. (2017). A somatic mutation in erythro-myeloid
37 progenitors causes neurodegenerative disease. Nature *549*, 389–393. 10.1038/nature23672.

24. Varatharaj, A., and Galea, I. (2017). The blood-brain barrier in systemic inflammation. Brain Behav Immun *60*, 1–12. 10.1016/j.bbi.2016.03.010.

25. Takata, F., Nakagawa, S., Matsumoto, J., and Dohgu, S. (2021). Blood-Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: Understanding of Cellular Events in Brain Microvascular Endothelial Cells for Prevention and Treatment of BBB Dysfunction. Front Cell Neurosci *15*, 661838. 10.3389/fncel.2021.661838.

26. Lakhan, S.E., Kirchgessner, A., Tepper, D., and Leonard, A. (2013). Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke. Front Neurol *4*, 32. 10.3389/fneur.2013.00032.

27. Spath, S., Komuczki, J., Hermann, M., Pelczar, P., Mair, F., Schreiner, B., and Becher, B. (2017). Dysregulation of the Cytokine GM-CSF Induces Spontaneous Phagocyte Invasion and Immunopathology in the Central Nervous System. Immunity *46*, 245–260. 10.1016/j.immuni.2017.01.007.

28. Donadieu, J., Larabi, I.A., Tardieu, M., Visser, J., Hutter, C., Sieni, E., Kabbara, N., Barkaoui, M., Miron, J., Chalard, F., et al. (2019). Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol *37*, 2857–2865. 10.1200/jco.19.00456.

29. Göthert, J.R., Gustin, S.E., Hall, M.A., Green, A.R., Göttgens, B., Izon, D.J., and Begley, C.G. (2005). In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood *105*, 2724–2732. 10.1182/blood-2004-08-3037.

30. Liu, Z., Gu, Y., Shin, A., Zhang, S., and Ginhoux, F. (2020). Analysis of Myeloid Cells in Mouse Tissues with Flow Cytometry. Star Protoc *1*, 100029. 10.1016/j.xpro.2020.100029.

31. Anderson, K.G., Mayer-Barber, K., Sung, H., Beura, L., James, B.R., Taylor, J.J., Qunaj, L., Griffith, T.S., Vezys, V., Barber, D.L., et al. (2014). Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc *9*, 209–222. 10.1038/nprot.2014.005.

32. Hamon, P., Loyher, P.-L., Chanville, C.B. de, Licata, F., Combadière, C., and Boissonnas, A. (2017). CX3CR1-dependent endothelial margination modulates Ly6Chigh monocyte systemic deployment upon inflammation in mice. Blood *129*, 1296–1307. 10.1182/blood-2016-08-732164.

33. Zhang, Y., Sloan, S.A., Clarke, L.E., Caneda, C., Plaza, C.A., Blumenthal, P.D., Vogel, H., Steinberg, G.K., Edwards, M.S.B., Li, G., et al. (2016). Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron *89*, 37–53. 10.1016/j.neuron.2015.11.013.

34. Remark, R., Merghoub, T., Grabe, N., Litjens, G., Damotte, D., Wolchok, J.D., Merad, M., and Gnjatic, S. (2016). In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci Immunol *1*, aaf6925. 10.1126/sciimmunol.aaf6925.

35. Török, O., Schreiner, B., Schaffenrath, J., Tsai, H.-C., Maheshwari, U., Stifter, S.A., Welsh, C., Amorim, A., Sridhar, S., Utz, S.G., et al. (2021). Pericytes regulate vascular immune homeostasis in the CNS. Proc National Acad Sci *118*. 10.1073/pnas.2016587118.

36. Brooks, S.P., and Dunnett, S.B. (2009). Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci *10*, 519–529. 10.1038/nrn2652.

1   37. Sugimoto, H., and Kawakami, K. (2019). Low-cost Protocol of Footprint Analysis and Hanging Box Test
2   for Mice Applied the Chronic Restraint Stress. J Vis Exp. 10.3791/59027.

3   38. Sengal, A., Velazquez, J., Hahne, M., Burke, T.M., Abhyankar, H., Reyes, R., Olea, W., Scull, B.,
4   Eckstein, O.S., Bigenwald, C., et al. (2021). Overcoming T-cell exhaustion in LCH: PD-1 blockade and
5   targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood *137*, 1777–1791.
6   10.1182/blood.2020005867.

7

8

10-20% *BRAFV600E*⁺ cells
5-10% *BRAFV600E*⁺ cells
<5% *BRAFV600E*⁺ cells

90-110 *BRAFV600E*⁺ cells / mm³
70-90 *BRAFV600E*⁺ cells / mm³
50-70 *BRAFV600E*⁺ cells / mm³

All Cells

Single Cells

Single Cells

Live

CD45⁺

neutrophils

CD11b⁻   CD11b⁺

YFP⁺